In vivo Antihyperglycemic and Antidyslipidemic Effects of L-Tartaric Acid.

Q2 Medicine Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2022-01-01 DOI:10.2174/1871529X23666221202091848

Ayoub Amssayef, Mohamed Eddouks

{"title":"In vivo Antihyperglycemic and Antidyslipidemic Effects of L-Tartaric Acid.","authors":"Ayoub Amssayef, Mohamed Eddouks","doi":"10.2174/1871529X23666221202091848","DOIUrl":null,"url":null,"abstract":"Aims: The aim of the study was to investigate the antihyperglycemic effect of L-Tartaric acid.Background: L-Tartaric acid is a natural product with possible beneficial effects on health.Objective: The goal of this work was to evaluate the antihyperglycemic and antidyslipidemic effects of L-Tartaric acid (L-TA) in rats.Materials and methods: In the first model, the effects of L-TA (10 and 40 mg/kg) on diabetes conditions induced by streptozotocin (STZ) in rats were investigated. In the second model, the effects of L-TA (40 and 80 mg/kg) on dyslipidemia induced by tyloxapol (Triton WR-1339) in rats were assessed.Results: L-TA (40 mg/kg) had improved all studied parameters. L-TA at 40 mg/kg was able to significantly reduce glycaemia, improve oral glucose tolerance (OGT), increase glycogen content in liver and extensor digitorum longus (EDL) muscle, and ameliorate the lipidic profile and atherogenic indices in STZ-diabetic rats.Conclusion: L-Tartaric acid was able to exhibit antihyperglycemic and antidyslipidemic effects in STZ-induced diabetic rats. Moreover, the antidyslipidemic effect of L-Tartaric acid was confirmed in tyloxapol-induced hyperlipidemic rats.","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":" ","pages":"185-198"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Disorders - Drug Targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X23666221202091848","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: The aim of the study was to investigate the antihyperglycemic effect of L-Tartaric acid.

Background: L-Tartaric acid is a natural product with possible beneficial effects on health.

Objective: The goal of this work was to evaluate the antihyperglycemic and antidyslipidemic effects of L-Tartaric acid (L-TA) in rats.

Materials and methods: In the first model, the effects of L-TA (10 and 40 mg/kg) on diabetes conditions induced by streptozotocin (STZ) in rats were investigated. In the second model, the effects of L-TA (40 and 80 mg/kg) on dyslipidemia induced by tyloxapol (Triton WR-1339) in rats were assessed.

Results: L-TA (40 mg/kg) had improved all studied parameters. L-TA at 40 mg/kg was able to significantly reduce glycaemia, improve oral glucose tolerance (OGT), increase glycogen content in liver and extensor digitorum longus (EDL) muscle, and ameliorate the lipidic profile and atherogenic indices in STZ-diabetic rats.

Conclusion: L-Tartaric acid was able to exhibit antihyperglycemic and antidyslipidemic effects in STZ-induced diabetic rats. Moreover, the antidyslipidemic effect of L-Tartaric acid was confirmed in tyloxapol-induced hyperlipidemic rats.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

左旋酒石酸的体内降血糖和降血脂作用

目的：本研究旨在探讨 L-酒石酸的降血糖作用：背景：L-酒石酸是一种可能对健康有益的天然产品：本研究的目的是评估L-酒石酸（L-TA）在大鼠体内的降血糖和降血脂作用：在第一个模型中，研究了 L-TA（10 和 40 mg/kg）对链脲佐菌素（STZ）诱导的糖尿病大鼠的影响。在第二个模型中，评估了 L-TA（40 和 80 毫克/公斤）对泰乐菌素（Triton WR-1339）诱导的大鼠血脂异常的影响：结果：L-TA（40 毫克/千克）改善了所有研究参数。结果：40 毫克/千克的 L-TA 能够显著降低 STZ 糖尿病大鼠的血糖，改善口服葡萄糖耐量（OGT），增加肝脏和伸肌（EDL）中的糖原含量，并改善血脂状况和动脉粥样硬化指数：结论：L-酒石酸对 STZ 诱导的糖尿病大鼠具有降血糖和降血脂作用。此外，L-酒石酸的降血脂作用在tyloxapol诱导的高脂血症大鼠中也得到了证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.